SU‐E‐T‐245: A Physics Database for a Multi‐Institutional Quality Consortium

Abstract

Purpose: A collaborative quality initiative (CQI) has been developed in the state of Michigan to assess physician and patient reported outcomes to compare conformal and IMRT techniques for a specific cohort of breast and lung cancer patients. Here, we present a web‐based database that was designed to collect planning and delivery information to facilitate analysis of outcomes for the CQI. Methods: A web‐based database was built to capture key physics information, including dose that may be related to acute toxicities. An annual institutional questionnaire captures the technology available for these patients. A patient‐specific survey collects simulation, planning, and delivery information. To overcome differences in DVH file formats, a simple interface was developed where the user selects from a structure list, submits numeric data, and reviews the data summary. To analyze the delivery type, DICOM‐RT plan files are uploaded via a web interface. The data are anonymized and displayed for the user to verify that no protected health information is submitted. Results: Initial partner institutions tested and provided feedback on all aspects of the physics data collection. Institutions have shared customized programs for extracting DVH and DICOM‐RT data and documents for electronic workflow. Data submission began via the web portal in April 2012. There are 4 planning systems represented among the 14 institutions. Delivery techniques include static, dynamic and segmental MLC, Tomotherapy, and VMAT. As of February, data have been submitted for approximately 80% of the 815 eligible cases. Centers will be audited for data quality once per year. Conclusion: A system has been designed to capture high integrity simulation, plan, and delivery data for a CQI focused on breast and lung cancer. This information will be used to quantitatively evaluate the use of IMRT techniques in the state of Michigan and to permit dose‐based correlations to physician and patient‐rated toxicities. This work was funded by Blue Cross Blue Shield of Michigan.